生物活性

• 描述Naftifine (Hydrochloride), a new antimycotic drug of the allylamine class, is a potent inhibitor of ergosterol biosynthesis in Candida albicans. Treated cells showed a dose-dependent drop in ergosterol content; the level was reduced by 60% at concentrations of greater than 50 mg/liter, causing total inhibition of growth. At 50 mg/liter, naftifine gave greater than 99% inhibition of sterol biosynthesis both in whole cells and in cell extracts of C. albicans^[1]. Naftifine exhibits an interesting in vitro spectrum of activity against dermatophytes (38 strains; minimal inhibitory concentration [MIC] range 0.1 to 0.2 microgram/ml), aspergilli (6 strains; MIC range, 0.8 to 12.5 microgram/ml), Sporothrix schenckii (2 strains; MICs, 0.8 and 1.5 microgram/ml), and yeasts of the genus Candida (77 strains; MIC range, 1.5 to greater than 100 microgram/ml)^[2]. Naftifine also has demonstrated anti-inflammatory properties such as a reduction in superoxide production and a reduction in polymorphonuclear leukocyte chemotaxis/endothelial adhesion^[3]. NAFT-2% (Naftifine HCl 2% cream) applied once daily for two weeks (one-half the treatment duration for naftifine 1% cream) is efficacious and safe for the treatment of T. cruris^[4].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT00750139	Tinea Pedis A... more >>thlete's Foot Collapse <<	Phase 3	Completed	-	United States, Alabama ... more >> Radiant Research Birmingham, Alabama, United States, 35209 United States, California Dr. Felix Sigal Los Angeles, California, United States, 90010-3209 University of California San Francisco, Dept of Dermatology San Francisco, California, United States, 94115 United States, Florida FXM Research Miami, Florida, United States, 33175 FXM Research Miramar, Florida, United States, 33027 United States, Illinois Glazer Dermatology Buffalo Grove, Illinois, United States, 60089 United States, Louisiana Tulane University Health Services New Orleans, Louisiana, United States, 70112 United States, Michigan Silverton Skin Institute Grand Blanc, Michigan, United States, 48439 United States, North Carolina Zoe Draelos, MD High Point, North Carolina, United States, 27262 United States, Ohio Haber Dermatology Euclid, Ohio, United States, 44118 United States, Oregon Oregon Dermatology and Research Center Portland, Oregon, United States, 97210 United States, Pennsylvania Paddington Testing Company Philadelphia, Pennsylvania, United States, 19103 Temple University School of Podiatric Medicine Philadelphia, Pennsylvania, United States, 19107 United States, South Carolina Coastal Carolina Research Center Mt. Pleasant, South Carolina, United States, 29464 United States, Texas J & S Studies College Station, Texas, United States, 77845 Research Across America Dallas, Texas, United States, 75234 Research Across America Plano, Texas, United States, 75093 Collapse <<
  NCT00253305	Onychomycosis	Phase 2	Completed	-	United States, Alabama ... more >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, Arizona Genova Clinical Research, Inc. Tucson, Arizona, United States, 85741 United States, Florida Greater Miami Skin and Laser Center Miami Beach, Florida, United States, 33140 United States, Missouri Washington University St. Louis, Missouri, United States, 63110 United States, Oregon Northwest Cutaneous research Portland, Oregon, United States, 97210 Collapse <<
  NCT02658292	Tinea Capitis	Phase 2	Withdrawn	-	-

• 更多
• 参考文献

• [1] Ryder NS, Seidl G, Troke PF. Effect of the antimycotic drug naftifine on growth of and sterol biosynthesis in Candida albicans. Antimicrob Agents Chemother. 1984;25(4):483‐487

  [2] Georgopoulos A, Petranyi G, Mieth H, Drews J. In vitro activity of naftifine, a new antifungal agent. Antimicrob Agents Chemother. 1981;19(3):386‐389

  [3] Gupta AK, Ryder JE, Cooper EA. Naftifine: a review. J Cutan Med Surg. 2008;12(2):51‐58

  [4] Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011;10(10):1142‐1147